About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Dr. Goldenberg discusses new drugs that have been approved for the treatment of hepatic disease, hypertension, and type 2 diabetes.
Marvin M. Goldenberg, PhD
The authors review the status of resources and requirements at 85 academic health centers in the U.S.
Alan H. Mutnick, PharmD, John A. Armitstead, MS, Thomas W. Cooley, BS, Kenneth Rockwell, Jr., PharmD, MS, and Karl A. Matuszewski, MS, PharmD
Editor-in-Chief David Nash examines Robert Kegan’s take on why people find it difficult to change.
David B. Nash, MD, MBA
Drug-related adverse events can be reduced when computerized pharmacy system alerts are fine-tuned on a regular basis.
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Mr. Barlas addresses the government’s interest in accelerating the availability of generic drugs.
The authors review a new agent, olmesartan medoxomil, for the treatment of hypertension.
Daryl Norwood, PharmD, Evans Branch III, PharmD, Bridget Smith, MD, and Marlon Honeywell, PharmD